These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25465967)

  • 1. Targeting the mechanisms of progression in castration-resistant prostate cancer.
    Ceder JA
    Eur Urol; 2015 Mar; 67(3):480-1. PubMed ID: 25465967
    [No Abstract]   [Full Text] [Related]  

  • 2. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on systemic therapy for advance prostate cancer.
    Carthon B; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):52-62. PubMed ID: 25637932
    [No Abstract]   [Full Text] [Related]  

  • 4. New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When.
    Roviello G; Generali D
    Clin Genitourin Cancer; 2019 Jun; 17(3):e534-e535. PubMed ID: 30827924
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
    Katzenwadel A; Wolf P
    Cancer Lett; 2015 Oct; 367(1):12-7. PubMed ID: 26185001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the treatment of castration resistant prostate cancer.
    Wadia R; Petrylak DP
    Asian J Androl; 2014; 16(4):555-60. PubMed ID: 24759588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F; Fizazi K
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-naïve prostate cancer: changing the LATITUDE.
    Klaassen Z; Murphy DG
    BJU Int; 2018 Jan; 121(1):9-11. PubMed ID: 28990349
    [No Abstract]   [Full Text] [Related]  

  • 14. Overcoming castration resistance in prostate cancer.
    Tsao CK; Small AC; Galsky MD; Oh WK
    Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer: Developing novel approaches to castration-sensitive disease.
    Francini E; Taplin ME
    Cancer; 2017 Jan; 123(1):29-42. PubMed ID: 27802360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen Deprivation Therapy for Advanced Prostate Cancer: Can Evolution Be Accelerated?
    Mohler JL
    J Natl Compr Canc Netw; 2016 Jun; 14(6):701-3. PubMed ID: 27283162
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
    Lorente D; Mateo J; Zafeiriou Z; Smith AD; Sandhu S; Ferraldeschi R; de Bono JS
    Nat Rev Urol; 2015 Jan; 12(1):37-47. PubMed ID: 25563847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
    Küronya Z; Bíró K; Gyergyay F; Géczi L
    Orv Hetil; 2017 Jan; 158(2):42-49. PubMed ID: 28088885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.